Established in 2024, Ambia Pharmaceuticals boasts robust commercialization capabilities and is primed to excel in Suppliers, Marketing, Production, High Quality, and Pharmaceutical sectors.
Our product line, featuring Ambizole-D, Seremo-LC, Nafinor, Zeftum-250/500, Aevoheme-XT, Kalseam, Kalseam-K2, Ainofit,and Many More is dedicated to serving society's well-being by combatting diseases and promoting a happy, healthy life.
At Ambia Pharmaceuticals, our vision is to emerge as the top-choice supply partner for our customers, achieving sustainable growth through a steadfast commitment to innovation, customer satisfaction, and the delivery of world-class quality products.
At Ambia Pharmaceuticals, we measure our success not just by our business performance, but also by our impact on the communities we serve and the environment in which we operate. Established on March 10, 2021, Ambia Pharmaceuticals is a privately owned company registered at the Registrar of Companies in Delhi. While classified as a non-governmental entity, we are committed to conducting our business with integrity and responsibility.
With an authorized share capital of Rs. 31,00000 and a paid-up capital of the same amount, our focus extends beyond mere financial figures. With over a year of experience in pharmaceuticals and marketing, we pride ourselves on fostering strong relationships with reputable vendors. Through their collaboration, we've been able to expand our product range to meet the diverse needs of our customers.
Our dedication to ethical business practices and community engagement underscores our commitment to making a positive difference in the lives of those we serve.
Happy Customers
Our Product
Employees
Countries